{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:33Z","timestamp":1793931813932,"version":"4.8.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of less aggressive, well-tolerated therapies. Pralatrexate is a novel antifolate with high affinity for reduced folate carrier-1. A dose de-escalation strategy identified recommended pralatrexate dosing for patients with CTCL that demonstrated high activity, good rates of disease control, and an acceptable toxicity profile for continuous long-term dosing. Eligibility included mycosis fungoides, S\u00e9zary syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression after \u2265 1 prior systemic therapy. The starting dose and schedule was 30 mg\/m2\/wk intravenously for 3 of 4 (3\/4) weeks. Subsequent starting doses were 20, 15, and 10 mg\/m2\/wk for 3\/4 or 2 of 3 (2\/3) weeks. Response was evaluated by the modified severity-weighted adjustment tool. Fifty-four patients were treated. The recommended regimen was identified as 15 mg\/m2\/wk for 3\/4 weeks and was explored in the expansion cohort. In 29 patients treated overall with the recommended dosing regimen, the median number of prior systemic therapies was 4. Pralatrexate was administered for a median of 4 cycles; response rate was 45%. The most common grade 3 adverse event (AE) was mucositis (17%); the only grade 4 AE was leukopenia (3%). Pralatrexate 15 mg\/m2\/wk for 3\/4 weeks shows high activity with acceptable toxicity in patients with relapsed\/refractory CTCL.<\/jats:p>","DOI":"10.1182\/blood-2011-11-390211","type":"journal-article","created":{"date-parts":[[2012,3,7]],"date-time":"2012-03-07T06:31:31Z","timestamp":1331101891000},"page":"4115-4122","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":116,"title":["Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma"],"prefix":"10.1182","volume":"119","author":[{"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Stanford Cancer Center, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"Yale Medical Oncology, Yale Cancer Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine M.","family":"Zain","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, New York University Langone Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Myskowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Chair in Medical Oncology, Washington University School of Medicine, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Delioukina","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Koutsoukos","sequence":"additional","affiliation":[{"name":"Allos Therapeutics Inc, Princeton, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Saunders","sequence":"additional","affiliation":[{"name":"Allos Therapeutics Inc, Princeton, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Irving Cancer Research Center, The New York Presbyterian Hospital\u2013Columbia University Medical Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111807424190700_B1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0889-8588(03)00117-5","article-title":"Primary cutaneous CD30-positive lymphoproliferative disorders.","volume":"17","author":"Willemze","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2019111807424190700_B2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach.","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"2019111807424190700_B3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"26","key":"2019111807424190700_B4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111807424190700_B5","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807424190700_B6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807424190700_B7","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807424190700_B8","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"issue":"29","key":"2019111807424190700_B9","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111807424190700_B10","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807424190700_B11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111807424190700_B12","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807424190700_B13","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome.","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111807424190700_B14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients.","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2019111807424190700_B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma.","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"issue":"1","key":"2019111807424190700_B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"13","key":"2019111807424190700_B17","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111807424190700_B18","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807424190700_B19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"2019111807424190700_B20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1517\/17425255.2011.595404","article-title":"Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.","volume":"7","author":"Foss","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2019111807424190700_B21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111807424190700_B22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.","volume":"42","author":"Sirotnak","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2019111807424190700_B23","first-page":"3493","article-title":"Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.","volume":"6","author":"Krug","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111807424190700_B24","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/JTO.0b013e31822adb19","article-title":"Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.","volume":"6","author":"Azzoli","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2019111807424190700_B25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-005-0080-x","article-title":"A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.","volume":"57","author":"Fury","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2019111807424190700_B26","first-page":"2072","article-title":"10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.","volume":"9","author":"Krug","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111807424190700_B27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.JTO.0000263715.84567.5f","article-title":"Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.","volume":"2","author":"Krug","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2019111807424190700_B28","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1158\/1078-0432.CCR-06-1754","article-title":"A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.","volume":"13","author":"Azzoli","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111807424190700_B29","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807424190700_B30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2009.80","article-title":"A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.","volume":"86","author":"Mould","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2019111807424190700_B31","article-title":"Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: phase 1 results [abstract].","author":"Horwitz","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"26","key":"2019111807424190700_B32","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111807424190700_B33","volume-title":"American Joint Committee on Cancer","author":"AJCC Cancer Staging Handbook","year":"2002","edition":"6th Ed"},{"issue":"6","key":"2019111807424190700_B34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111807424190700_B35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/18\/4115\/1351977\/zh801812004115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/18\/4115\/1351977\/zh801812004115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:54:56Z","timestamp":1574081696000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/18\/4115\/30043\/Identification-of-an-active-welltolerated-dose-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,3]]},"references-count":35,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,5,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-390211","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,3]]}}}